part a inclusion criteria: 1. men and women ≥ 18 years of age on the day of inclusion (no upper limit). 2. presence of two or more of the following covid-19 symptoms with an onset within 7 days of dosing: feeling hot or feverish, cough, sore throat, low energy, or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. 3. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). 4. understand and agree to comply with the planned study procedures. 5. the patient or legally authorized representative give signed informed consent. part a

part a inclusion criteria: 1. men and women ≥ 18 years of age on the day of inclusion (no upper limit). 2. presence of two or more of the following covid-19 symptoms with an onset within 7 days of dosing: feeling hot or feverish, cough, sore throat, low energy, or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. 3. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). 4. understand and agree to comply with the planned study procedures. 5. the patient or legally authorized representative give signed informed consent. part a

part a inclusion criteria: men and women ≥ 18 years of age on the day of inclusion (no upper limit). presence of two or more of the following covid-19 symptoms with an onset within 7 days of dosing: feeling hot or feverish, cough, sore throat, low energy, or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). understand and agree to comply with the planned study procedures. the patient or legally authorized representative give signed informed consent. part a

part a inclusion criteria: men and women ≥ 18 years of age on the day of inclusion (no upper limit). presence of two or more of the following covid-19 symptoms with an onset within 7 days of dosing: feeling hot or feverish, cough, sore throat, low energy, or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). understand and agree to comply with the planned study procedures. the patient or legally authorized representative give signed informed consent. part a

part a inclusion criteria: males or females ≥ 18 years of age on the day of inclusion (no upper limit). presence of two or more covid-19 symptoms and onset within 7 days prior to dosing: feeling hot or feverish, cough, sore throat, low energy or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). understands and agrees to comply with the planned study procedures. the patient or legally authorized representative gives signed informed consent. part a

part a inclusion criteria: males or females ≥ 18 years of age on the day of inclusion (no upper limit). presence of two or more covid-19 symptoms and onset within 7 days prior to dosing: feeling hot or feverish, cough, sore throat, low energy or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). understands and agrees to comply with the planned study procedures. the patient or legally authorized representative gives signed informed consent. part a

inclusion criteria: men or women ≥ 18 years of age on the day of inclusion (no upper limit). presence of two or more covid-19 symptoms and onset within 7 days prior to dosing: feeling hot or feverish, cough, sore throat, low energy or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). understand and agree to comply with the planned study procedures. the patient or legally authorized representative give signed informed consent.

inclusion criteria: men or women ≥ 18 years of age on the day of inclusion (no upper limit). presence of two or more covid-19 symptoms and onset within 7 days prior to dosing: feeling hot or feverish, cough, sore throat, low energy or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). understand and agree to comply with the planned study procedures. the patient or legally authorized representative give signed informed consent.

inclusion criteria: 1. men or women ≥ 18 years of age on the day of inclusion (no upper limit). 2. presence of two or more covid-19 symptoms and onset within 7 days prior to dosing: feeling hot or feverish, cough, sore throat, low energy or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. 3. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). 4. understand and agree to comply with the planned study procedures. 5. the patient or legally authorized representative give signed informed consent.

inclusion criteria: 1. men or women ≥ 18 years of age on the day of inclusion (no upper limit). 2. presence of two or more covid-19 symptoms and onset within 7 days prior to dosing: feeling hot or feverish, cough, sore throat, low energy or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. 3. positive test for sars-cov-2 in upper respiratory swab on the day of dosing (rapid antigen test). 4. understand and agree to comply with the planned study procedures. 5. the patient or legally authorized representative give signed informed consent.